Inhibition or genetic deletion of USP7 disrupts multiple alkylation damage repair pathways, raising the possibility that USP7 could be targeted to enhance the efficacy of combination chemotherapy, including TMZ and other alkylating agents, by modulating distinct repair mechanisms in GBM. Here, USP7 is linked to glioblastoma.